Modern Rheumatology

, Volume 23, Issue 3, pp 450–455 | Cite as

Clinical results of alendronate monotherapy and combined therapy with menatetrenone (VitK2) in postmenopausal RA patients

  • Kouji Suzuki
  • Shigeyoshi Tsuji
  • Yaeko Fukushima
  • Takanobu Nakase
  • Masayuki Hamada
  • Tetsuya Tomita
  • Hideki Yoshikawa
Original Article



We aimed to evaluate the clinical efficacy of monotherapy with alendronate and combined therapy with alendronate and menatetrenone (vitamin K2 [VitK2]) in postmenopausal rheumatoid arthritis (RA) patients with osteoporosis or osteopenia.


Sixty-two postmenopausal RA patients with untreated osteoporosis or osteopenia (lumbar spine bone density ≤80 % of young adult mean [YAM]) were enrolled: 39 had abnormal serum undercarboxylated osteocalcin (ucOC) levels (>4.5 ng/mL) and received combined therapy with alendronate (35 mg/week) and VitK2 (45 mg/day) (ALN + K group); 23 had normal ucOC levels (≤4.5 ng/mL) and received alendronate monotherapy (35 mg/week) (ALN group). The clinical results for the 57 patients in both groups were evaluated after 1-year treatment.


The mean baseline/follow-up (FU) lumbar spine bone density (%YAM) values were 73.0/76.8 % (P < 0.01) in the ALN + K group and 77.0/80.3 % (P < 0.01) in the ALN group; a significant increase was shown in both groups. Mean proximal femoral bone density values at baseline/FU were 71.4/73.8 (P < 0.01) in the ALN + K group and 71.4/71.6 % (not significant; NS) in the ALN group; a significant increase was shown in the ALN + K group only. Serum ucOC levels were normalized in the ALN + K group at FU. At FU, bone metabolism markers [bone-specific alkaline phosphatase (BAP) and N-terminal cross-linked telopeptides of type I collagen] were decreased in both groups. One patient in the ALN + K group and three in the ALN group suffered new fractures.


Combined therapy with alendronate and VitK2 decreases bone metabolism marker levels and serum ucOC levels, and increases lumbar spine and femoral neck bone density in postmenopausal RA patients with abnormal ucOC levels and osteoporosis or osteopenia.


Undercarboxylated osteocalcin (ucOC) Rheumatoid arthritis (RA) Menatetrenone (VitK2Alendronate (ALN) Osteoporosis 


Conflict of interest



  1. 1.
    Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43:522–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:3104–12.PubMedCrossRefGoogle Scholar
  3. 3.
    No authors listed. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement. 2000;17:1–45.Google Scholar
  4. 4.
    Sorensen OH, Crawford GM, Mulder H, Hosking DJ, Gennari C, Mellstrom D, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32:120–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten year’s experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Feskanich D, Weber P, Willet WC, Rockett H, Booth SL, Colditz GA. Vitamin K intake and hip fractures in women: a prospective study. Am J Clin Nutr. 1999;69:74–9.PubMedGoogle Scholar
  7. 7.
    Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137–48.PubMedCrossRefGoogle Scholar
  8. 8.
    Yilmaz L, Ozoran K, Gündüz OH, Uçan H, Yücel M. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. Rheumatol Int. 2001;20:65–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, et al. Prevention of loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Kai M, Makino S, Yuasa M, Nishijima T. Study of bone vitamin K deficiency of RA patients-Evaluation with the measurement of ucOC in serum. Rheumatology.2009;42:133–8 (in Japanese).Google Scholar
  11. 11.
    Hirao M, Hashimoto J, Ando W, Ono T, Yoshikawa H. Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women. J Bone Miner Metab. 2008;26:260–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Nakayama H, Hagiwara F, Tohma S. Three-year effects of bisphosphonates on treatment of osteoporosis and on reducing the risk for vertebral fractures of rheumatoid arthritis patients. Osteoporos Japan. 2007;15:13–8.Google Scholar
  13. 13.
    Iwamoto J, Takeda T, Ichimura S. Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis. J Orthop Sci. 2000;5:546–51.PubMedCrossRefGoogle Scholar
  14. 14.
    Knapen MH, Schurgers LJ, Vermeer C. Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women. Osteoporos Int. 2007;18:963–72.PubMedCrossRefGoogle Scholar

Copyright information

© Japan College of Rheumatology 2012

Authors and Affiliations

  • Kouji Suzuki
    • 1
  • Shigeyoshi Tsuji
    • 1
  • Yaeko Fukushima
    • 2
  • Takanobu Nakase
    • 1
  • Masayuki Hamada
    • 1
  • Tetsuya Tomita
    • 3
  • Hideki Yoshikawa
    • 3
  1. 1.Department of Orthopaedic SurgeryHoshigaoka Koseinenkin HospitalHirakataJapan
  2. 2.Osaka Trauma and Microsurgery Center, Seikeikai HospitalSakaiJapan
  3. 3.Department of OrthopaedicsOsaka University Graduate School of MedicineSuitaJapan

Personalised recommendations